PCN67 COST-EFFECTIVENESS ANALYSIS OF DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY IN PORTUGAL

Autor:	Margarida Borges, Rita Guerreiro, J. Anjo, M. Gouveia, A.T. Paquete, C. Magalhaes
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty business.industry Bortezomib Health Policy Public Health Environmental and Occupational Health Daratumumab Cost-effectiveness analysis medicine.disease Prior Therapy Internal medicine medicine business Multiple myeloma Dexamethasone medicine.drug
Zdroj:	Value in Health. 22:S448
ISSN:	1098-3015
DOI:	10.1016/j.jval.2019.09.264
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::2ab61ad3ea731710899a49c4fd387e9a https://doi.org/10.1016/j.jval.2019.09.264 Zobrazit plný text záznamu Full Text from ScienceDirect